Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 3.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,731,045 shares of the company’s stock after buying an additional 64,744 shares during the quarter. Geode Capital Management LLC’s holdings in Travere Therapeutics were worth $24,222,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. CWM LLC raised its position in Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after acquiring an additional 3,065 shares in the last quarter. DRW Securities LLC acquired a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $95,000. Quarry LP bought a new stake in shares of Travere Therapeutics in the 3rd quarter worth approximately $105,000. Forefront Analytics LLC lifted its stake in Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in Travere Therapeutics during the second quarter worth approximately $117,000.

Travere Therapeutics Price Performance

Shares of TVTX opened at $17.28 on Friday. The business’s 50-day moving average is $18.11 and its 200-day moving average is $13.35. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -3.80 and a beta of 0.69. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $20.33.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same quarter in the prior year, the business earned ($1.17) EPS. The company’s revenue for the quarter was up 69.6% compared to the same quarter last year. Equities research analysts expect that Travere Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on TVTX shares. Wedbush upped their price target on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. HC Wainwright cut their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, September 27th. Leerink Partners reiterated an “outperform” rating and issued a $20.00 price target on shares of Travere Therapeutics in a research report on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Finally, Guggenheim raised their target price on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.67.

Insider Activity

In related news, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. This trade represents a 21.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey A. Meckler sold 40,000 shares of the company’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $14.06, for a total value of $562,400.00. Following the completion of the transaction, the director now directly owns 81,000 shares in the company, valued at approximately $1,138,860. The trade was a 33.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,090 shares of company stock worth $1,631,147 in the last ninety days. Corporate insiders own 4.06% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.